Program
TQA3810
A development code. Also written as “TQA3810 tablets+NUC”.
In Sino Biopharmaceutical's pipeline, TLR-8激动剂
. Its studies are mostly in Hepatitis B, Chronic, led by Sino Biopharmaceutical.
Furthest: phase 2, since Aug 20, 20242 company-led studies, 1 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sino Biopharmaceutical | 21 open or running | phase 2since Aug 20, 2024 | May 21, 2024 | none ahead |
- Named in Sino Biopharmaceutical’s own pipeline as
TQA3810
, phase 2, as of Nov 16, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 21, 2024First study: phase 1 study in Hepatitis B, ChronicFirst studyNCT06431438 · 759 enrolled · China
- Aug 20, 2024Phase 2 study in Hepatitis B, ChronicNCT06566248 · 90 planned · China
TargetBeta
“TLR-8激动剂”the company's pipeline, read by Claude · source
Other programs on TLR8
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| resiquimodrule | Staidson (Beijing) Biopharmaceuticals | phase 3 | 14 |
| enpatoranrule | Merck KGaA, Darmstadt, Germany | phase 3 | 12 |
| afimetoranrule | Bristol-Myers Squibb | phase 3 | 12 |
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06566248Hepatitis B, Chronic · China | 2 | Recruiting | Sep 2024 | 90 |
| NCT06431438Hepatitis B, Chronic · China | 1 | Completed | Nov 20, 2023 | 759 |
How it is read
Names in the registry
- “TQA3810 tablets+NUC”, 1 entry
- “TQA3810”, 1 entry
Codes read as this program: TQA3810.
Conditions, from the studies’ own filings
- Hepatitis B, Chronic, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.